Council Members in this Study Group: 459
Leading institutions connect with members of this Study Group through GLG
Daniel Wynn, MDDirector of Clinical Research
CONSULTANTS IN NEUROLOGY LTD ![]()
Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke,chronic...
Marina Raikhel, MDDirector
TORRANCE MEMORIAL MEDICAL CENTER ![]()
Marina Raikhel, MD, is an active family practitioner with a particular interest in primary care and ob/gyn focus. She has expertise in the treatment of a wide variety of internal medicine conditions, with special focus on diabetes, hypertension, obesity, anxiety, and depression. She is Director ofTorrance...
President/Owner
Doctors of Pharmacy, Inc. ![]()
David Zimmerman, PharmD, FASCP, is the President and an Independent Consultant of Doctors of Pharmacy. Dr. Zimmerman formerly served as the Director of Clinical Affairs at Employee Health Insurance Management, a pharmacy benefit manager. He has over 30 years of experience, specializing in pharmacyservices...
Chief of Psychiatry and Psychology
CHILDREN'S HOSPITAL OF MICHIGAN ![]()
David Rosenberg, MD, is a tenured Professor and Miriam L Hamburger Endowed Chair of Psychiatry at Wayne State University and the Children's Hospital of Michigan. He is a board certified general and adult psychiatrist and pediatric psychiatrist. Dr. Rosenberg has authored first ever textbook on pediatric...
Amit Vijapura, MDOwner
AMIT VIJAPURA MD ![]()
Amit Vijapura, MD, is a Private Practitioner in Psychiatry based in Florida. He has over 15 years of experience in the field and has expertise in depression, bipolar disorder, anxiety disorder, attention deficient disorder, and schizophrenia. Dr. Vijapura is board certified in Psychiatry and is also...
Psychiatrist
North Scottsdale Psychiatric Specialists ![]()
Robert Schulte, MD, is a Private Practitioner and a Psychiatrist at North Scottsdale Psychiatric Specialists in Arizona. He is board certified in Adult Psychiatry and Child and Adolescent Psychiatry with extensive experience with children and adult's re-psychotherapy and psychopharmacology and thetreatment...
Founder and Director
Institute for Integrative Psychiatry ![]()
Rami Kaminski, MD, is Director and Founder of the Institute for Integrative Psychiatry in New York, a not-for-profit organization aimed at evaluating current psychiatric services and how they integrate with medicine, such as the mutual effects between medical and psychiatric conditions. Prior to that,...
President
RED OAK PSYCHIATRY ASSOCIATES, P. A. ![]()
Lawrence Ginsberg, MD, is President and CEO of Red Oak Psychiatry Associates, PA, a multidisciplinary mental health group in Houston, Texas. Dr. Ginsberg's research interests include psychopharmacology, addiction medicine, and forensic psychiatry. His areas of clinical expertise are attention deficit...
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Lurasidone will be an important new option for the treatment of Schizophrenia
August 29, 2009
LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY | www.pipelinereview.com
After much disappointment over the current Atypical Antipsychotics , Lurasidone shows great promise for treatment refractory Schizophrenics.
New Treatment Option for the Hearing Impaired
August 22, 2009
Oticon Medical Receives FDA Clearance To Market Innovative Bone Anchored Hearing System | www.medicalnewstoday.com
Oticon's new bone anchored hearing implant might offer unique advantages to the hearing impaired.
Treatment of Social Anxiety Disorderved
August 6, 2009
NeuroSearch successfully advances NSD-721 for treatment of social anxiety disorder and receives EUR 5 million in equity financing under the alliance with GlaxoSmithKline | www.pipelinereview.com
NeuroSearch new drug NSD-721 will be of great benefit to patients with Social Anxiety Disorder.
Is this the end of Bifeprunoxyndrome.
August 3, 2009
Lundbeck, Solvay discontinue all joint R&D activities for bifeprunox to treat schizophrenia | www.pharmabiz.com
Bifeprunox initially looked like it might be a blockbuster for Solvoy when it was first studied.
Sex - we can chemically get it up and now last longer?
August 2, 2009
Sciele Pharma And Plethora Solutions Announce Positive Results Of Final Phase III Pivotal Trial For PSD502 For Premature Ejaculation | www.medicalnewstoday.com
?? breakthrough
| Study Group Name | No. Members |
|---|---|
| Psychiatrists (US) | 1155 |
| Psychiatrists | 1554 |
| Physicians who Treat Schizophrenia (US) | 371 |
| Physicians who Treat Depression (US) | 450 |
| Effexor XR Prescribers (US) | 148 |
| SSRI Prescribers (US) | 278 |
| Seroquel Prescribers forSchizophrenia (US) | 109 |